Pyxis Oncology, Inc. (PYXS) is a biotechnology company focused on the development of novel cancer therapies. As with any investment, it is important to perform a technical analysis to gain insights into the stock's performance. By analyzing various technical indicators, investors can make informed decisions about buying or selling PYXS stock.

Technical indicators provide valuable information about a stock's price movements. One such indicator is the Relative Strength Index (RSI), which measures the momentum and speed of price changes. A high RSI value may indicate an overbought stock, while a low RSI value may suggest an oversold stock.

Pyxis Oncology (PYXS) Technical Analysis

Learn about Pyxis Oncology, Inc. (PYXS) stock technical analysis with indicators including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Gain insights into the stock's performance and trends. Explore the potential of Pyxis Oncology, Inc. (PYXS) with our comprehensive technical analysis report.

PYXS Technical Analysis: Indicators, RSI, ADX, MACD and More

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	40.99	Neutral	-
auto_graphMACD	-40.75	Neutral	998.5%
auto_graphCCI	-75.80	Neutral	142.3%
auto_graphADX	13.72	Neutral	-
auto_graphATR	123.45	Buy	-
auto_graphWILLR	-96.56	Buy	929.1%
auto_graphROC	-83.51	Neutral	126.4%
auto_graphSTOCHRSI	77.03	Neutral	714.0%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Pyxis Oncology (PYXS) Technical Analysis

Keep an eye on Pyxis Oncology

Frequently Asked Questions

What are the technical signals for Pyxis Oncology (PYXS) stock based on the last 30 days?

Take Your Investments to a Whole New Level